With the advancement of new variants, researchers are trying to determine how different vaccines can cope with these coronavirus mutations. Now, a study evaluated what happens to Delta strain and Sinopharm, one of the vaccines that are being applied massively at this stage of the vaccination campaign in Argentina. And they discovered that although it generates a solid protection, the immune response is lower than against the original strain.
This studio, the first to evaluate Sinopharm against Delta, was not yet published in any peer-reviewed journal but was published on the MedRxiv site, a platform where unpublished research is uploaded that will later be validated in scientific journals.
The research was carried out by scientists from the University of Sri Jayewardenepura, in Sri Lanka, the Municipal Council of Colombo (another city in the Asian country) and the University of Oxford.
The study was conducted in 282 people, and the authors indicated that the Chinese vaccine elicited an antibody response (seroconversion) of the 95% against SARS-CoV-2 spike protein.
However, according to information released by Reuters, those who received the Sinopharm vaccine had a 1.38 reduction in your immune response versus Delta compared to the original Wuhan strain. Regarding the Beta variant, previously called South African, the reduction in antibody levels is more pronounced, 10 points.
But the researchers noted that there are no differences in the levels of antibodies against the two variants between people vaccinated with Sinopharm and those who had been naturally infected with SARS-CoV-2, suggesting that the vaccine induces an antibody response similar to having had Covid.
For Neelika Malavige, head of the department of Immunology at the University of Sri Jayewardenepura, “the conclusion of this research is that when we talk about Delta and other variants, the Sinopharm vaccine induces similar responses as naturally infected people, which is very good”.
“Among the groups aged 20 to 40 years, 98% developed antibodies, while in the group over 60, 93% did. This is not surprising because older people respond less to vaccines ”, added the specialist.
So far, Sinopharm is the vaccine that Argentina received the most doses. This Tuesday, a shipment of another 768,000 doses arrived in Ezeiza, and there are already 12,144 million that have arrived in the country. Thus, China displaced Sputnik at the top of the basket of vaccines, of which just over 11.86 million have arrived so far, most of the first component.